VolitionRX Appoints MBL as Distributor for Nu.Q Discover Assays in Japan

Reuters

Feb 10

VolitionRX Appoints MBL as Distributor for <a href="https://laohu8.com/S/NU">Nu</a>.Q Discover Assays in Japan

VolitionRx Limited has announced the appointment of Medical & Biological Laboratories Co. Ltd (MBL) as a non-exclusive distributor of its Nu.Q® Discover assays in Japan. The company also reported the first agreement with a leading pharmaceutical company to utilize its Nu.Q® Discover biomarkers in a longitudinal Phase 1/2b clinical study, marking the first in-human clinical use of these biomarkers. Additionally, VolitionRx highlighted the commercial sale of its High Throughput Synthetic Sepsis method, which measures Neutrophil Extracellular Traps (NETs) activation and inhibition in whole blood. Through its Nu.Q® Discover platform, VolitionRx is now serving close to 100 clients worldwide, including pharmaceutical and diagnostic companies, some of which have advanced to late-stage clinical trials using VolitionRx assays as pharmacodynamic biomarkers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN84570) on February 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610914628"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610914628\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610914628?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-10 21:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610914628","market":"us","top_or_hot":-1,"title":"VolitionRX Appoints MBL as Distributor for Nu.Q Discover Assays in Japan","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      VolitionRX Appoints MBL as Distributor for <a href=\"https://laohu8.com/S/NU\">Nu</a>.Q Discover Assays in Japan\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        VolitionRx Limited has announced the appointment of Medical &amp; Biological Laboratories Co. Ltd (MBL) as a non-exclusive distributor of its Nu.Q® Discover assays in Japan. The company also reported the first agreement with a leading pharmaceutical company to utilize its Nu.Q® Discover biomarkers in a longitudinal Phase 1/2b clinical study, marking the first in-human clinical use of these biomarkers. Additionally, VolitionRx highlighted the commercial sale of its High Throughput Synthetic Sepsis method, which measures Neutrophil Extracellular Traps (NETs) activation and inhibition in whole blood. Through its Nu.Q® Discover platform, VolitionRx is now serving close to 100 clients worldwide, including pharmaceutical and diagnostic companies, some of which have advanced to late-stage clinical trials using VolitionRx assays as pharmacodynamic biomarkers.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/VNRX\">VolitionRX Ltd</a>. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN84570) on February 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VolitionRX Appoints MBL as Distributor for Nu.Q Discover Assays in Japan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVolitionRX Appoints MBL as Distributor for Nu.Q Discover Assays in Japan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-10 21:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      VolitionRX Appoints MBL as Distributor for <a href=\"https://laohu8.com/S/NU\">Nu</a>.Q Discover Assays in Japan\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        VolitionRx Limited has announced the appointment of Medical &amp; Biological Laboratories Co. Ltd (MBL) as a non-exclusive distributor of its Nu.Q® Discover assays in Japan. The company also reported the first agreement with a leading pharmaceutical company to utilize its Nu.Q® Discover biomarkers in a longitudinal Phase 1/2b clinical study, marking the first in-human clinical use of these biomarkers. Additionally, VolitionRx highlighted the commercial sale of its High Throughput Synthetic Sepsis method, which measures Neutrophil Extracellular Traps (NETs) activation and inhibition in whole blood. Through its Nu.Q® Discover platform, VolitionRx is now serving close to 100 clients worldwide, including pharmaceutical and diagnostic companies, some of which have advanced to late-stage clinical trials using VolitionRx assays as pharmacodynamic biomarkers.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/VNRX\">VolitionRX Ltd</a>. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN84570) on February 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VNRX","symbol_name":"VolitionRX Ltd","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDL6p24xP:1","article_id":"2610914628","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610914628","pubTimestamp":1770728835,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"VolitionRx Limited has announced the appointment of Medical & Biological Laboratories Co. Ltd  as a non-exclusive distributor of its Nu.Q Discover assays in Japan. The company also reported the first agreement with a leading pharmaceutical company to utilize its Nu.Q Discover biomarkers in a longitudinal Phase 1/2b clinical study, marking the first in-human clinical use of these biomarkers. Additionally, VolitionRx highlighted the commercial sale of its High Throughput Synthetic Sepsis method, which measures Neutrophil Extracellular Traps  activation and inhibition in whole blood. Through its Nu.Q Discover platform, VolitionRx is now serving close to 100 clients worldwide, including pharmaceutical and diagnostic companies, some of which have advanced to late-stage clinical trials using VolitionRx assays as pharmacodynamic biomarkers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VNRX":"VolitionRX Ltd","BK4198":"医疗保健用品"},"translate_title":"VolitionRX任命MBL为Nu.Q Discover Assays在日本的经销商","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VNRX":0.9},"content_text":"VolitionRX Appoints MBL as Distributor for Nu.Q Discover Assays in Japan\n    \n\n        VolitionRx Limited has announced the appointment of Medical & Biological Laboratories Co. Ltd (MBL) as a non-exclusive distributor of its Nu.Q® Discover assays in Japan. The company also reported the first agreement with a leading pharmaceutical company to utilize its Nu.Q® Discover biomarkers in a longitudinal Phase 1/2b clinical study, marking the first in-human clinical use of these biomarkers. Additionally, VolitionRx highlighted the commercial sale of its High Throughput Synthetic Sepsis method, which measures Neutrophil Extracellular Traps (NETs) activation and inhibition in whole blood. Through its Nu.Q® Discover platform, VolitionRx is now serving close to 100 clients worldwide, including pharmaceutical and diagnostic companies, some of which have advanced to late-stage clinical trials using VolitionRx assays as pharmacodynamic biomarkers.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN84570) on February 10, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}